This episode reviews the key takeaways from the ADAURA trial, discusses strategies for protecting the CNS in EGFR-mutated NSCLC, and examines the impact ADAURA had on recurrence rates in patients with completely resected EGFR-mutated NSCLC who were previously treated with adjuvant chemotherapy.
Comment on the key takeaways from the ADAURA trial.
What are your thoughts on protecting the CNS?
In your experience, what is the average disease recurrence rate among patients with completely resected EGFR-mutated early or locally advanced NSCLC treated with adjuvant chemotherapy alone? What was your experience prior to ADAURA, and how has ADAURA changed that since?